GOODWILL AND OTHER INTANGIBLE ASSETS

6 Months Ended

Jun. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill

Changes in the carrying amount of goodwill for the six-month period ended June 30, 2023 were as follows:


Dollars in thousands	Codman Specialty Surgical		Tissue Technologies		Total
Goodwill at December 31, 2022	$	656,219	$	382,662	$	1,038,881
SIA Acquisition Working Capital Adjustment	—		(382)		(382)
Foreign currency translation	3,015		1,759		4,774
Goodwill at June 30, 2023	$	659,234	$	384,039	$	1,043,273

The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative analysis. In the second quarter of 2023, due to the voluntary recall of Primatrix®, Surgimend®, Revize™, and TissueMend™ as well as the

associated drop in the Company's stock price in Q2, the Company elected to perform a quantitative analysis for its Tissue Technologies reporting unit.

The quantitative test estimates the fair value of the reporting unit using a discounted cash flow model, which incorporates significant estimates and assumptions made by management which, by their nature, are characterized by uncertainty. The quantitative test utilized a long-term growth rate of 2% and a discount rate of 10%. The Company determined, after performing the quantitative analysis, that the fair value of the goodwill of the reporting unit was not less than the carrying amount, with more than 20% headroom.

Other Intangible Assets

The components of the Company’s identifiable intangible assets were as follows:


	June 30, 2023
Dollars in thousands	Weighted Average Life	Cost		Accumulated Amortization		Net
Completed technology	18 years	$	1,211,660	$	(408,428)	$	803,232
Customer relationships	12 years	$	193,550	$	(148,103)	$	45,447
Trademarks/brand names	28 years	$	97,950	$	(36,700)	$	61,250
Codman tradename	Indefinite	$	169,279	$	—	$	169,279
Supplier relationships	30 years	$	30,211	$	(17,659)	$	12,552
All other	11 years	$	6,064	$	(4,228)	$	1,836
		$	1,708,714	$	(615,118)	$	1,093,596


	December 31, 2022
Dollars in thousands	Weighted Average Life	Cost		Accumulated Amortization		Net
Completed technology	18 years	$	1,204,325	$	(370,968)	$	833,357
Customer relationships	12 years	193,081		(144,040)		49,041
Trademarks/brand names	28 years	97,265		(34,674)		62,591
Codman tradename	Indefinite	166,693		—		166,693
Supplier relationships	30 years	30,211		(17,170)		13,041
All other	11 years	5,957		(4,071)		1,886
		$	1,697,532	$	(570,923)	$	1,126,609

Based on quarter-end exchange rates, amortization expense (including amounts reported in cost of goods sold) is expected to be approximately $41.4 million for the remainder of 2023, $82.2 million in 2024, $82.2 million in 2025, $82.0 million in 2026, $80.0 million in 2027, $78.5 million in 2028 and $477.1 million thereafter.

The Company periodically performs testing for impairment on certain long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the second quarter of 2023, due to the voluntary recall of Primatrix®, Surgimend®, Revize™, and TissueMend™, the Company elected to perform impairment testing on certain definite lived intangibles.

The impairment testing estimates the fair value of the intangibles using an undiscounted cash flow model. The Company determined, after performing the impairment testing, that the fair value of the intangibles was not less that the carrying amount.